Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targretin in non-small cell lung cancer
NCT00050960Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2002
- Primary completion
- Jul 2004
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of bexarotene in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Overall Survival. Started May 2002; status: completed.
02
Drugs
bexarotene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00050960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050960.